Over 90 Total Lots Up For Auction at One Location - WA 04/08

Gamma Medica expands into European breast imaging market through partnership with medical supplies distributor

Press releases may be edited for formatting or style | February 21, 2017 Business Affairs Women's Health
SALEM, N.H.--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced it has partnered with Hospital Services Limited (HSL), an established medical device company that distributes, installs and services radiology capital equipment and medical devices. This partnership will provide women with dense breast tissue access to Gamma Medica’s LumaGEM® Molecular Breast Imaging system in the United Kingdom, Ireland and the Channel Islands.

Women are eligible for the United Kingdom’s NHS breast screening programme at age 50-79 years, with women being invited to be screened every three years.1 Similarly in Ireland, women 50-69 years-old are eligible for breast screenings every two years.2 Dense breast tissue not only increases the risk of developing breast cancer, but decreases the visibility of a cancer on conventional mammograms and other forms of anatomical imaging devices. Dense breast tissue and cancer both appear white on mammograms making it difficult to distinguish between the two—it’s like trying to find a snowflake in a snowstorm. This may lead to false negatives, unwarranted biopsies or delayed diagnoses.3

Ideal for dense breast tissue, MBI is a groundbreaking technology that significantly improves early detection of breast cancer in women with dense breast tissue. The technology has proven to be as effective as a secondary screening method compared to ultrasound or MRI with far fewer false positives.4 Peer-reviewed clinical research reports the use of LumaGEM MBI reduces the need for tissue biopsies by 50 percent compared to other modalities.4 MBI is also more comfortable and better tolerated by most patients than conventional mammography or MRI.
stats
DOTmed text ad

New Fully Configured 80-slice CT in 2 weeks with Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.

stats
“We are pleased that through our collaboration with HSL, women with dense breasts in the UK, Ireland and the Channel Islands, will soon have access to the LumaGEM MBI technology,” said Philip Croxford, Gamma Medica President and CEO. “This partnership is the first step in Gamma Medica’s global expansion to increase awareness and access to clinical superior breast imaging technology worldwide. Leveraging HSL’s network enables Gamma Medica to continue to promote early detection on an international scale.”

A breakthrough retrospective study, which complemented earlier published prospective clinical research, was published in the American Journal of Roentgenology’s August issue.5 This retrospective study monitored over 1,700 women with dense breast tissue over a three-year period. The study confirmed LumaGEM’s additional cancer detection rate of 7.7 cancers per 1,000, an increase from three cancers per 1,000 with mammography alone. The study also concluded that of the additional breast cancers found, approximately 85 percent of these cancers were invasive and node negative, indicating they were detected at an early stage and therefore presented the patient with the likelihood of a better prognosis.6

You Must Be Logged In To Post A Comment